Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aslan Pharmaceuticals Ltd ASLN

Healthcare Biotechnology
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness... see more

Recent & Breaking News (NDAQ:ASLN)

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

GlobeNewswire March 10, 2023

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

GlobeNewswire March 8, 2023

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

GlobeNewswire February 28, 2023

ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M

GlobeNewswire February 24, 2023

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

GlobeNewswire February 24, 2023

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

GlobeNewswire January 3, 2023

ASLAN Pharmaceuticals Announces Participation in January Investor Conferences

GlobeNewswire December 16, 2022

ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

GlobeNewswire December 15, 2022

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 21, 2022

ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference

GlobeNewswire November 8, 2022

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire October 28, 2022

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting

GlobeNewswire September 28, 2022

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

GlobeNewswire September 14, 2022

ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

GlobeNewswire September 13, 2022

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire September 7, 2022

ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 2, 2022

ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy(TM) Image Capture Software in Atopic Dermatitis Clinical Trials

GlobeNewswire August 25, 2022

ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022

GlobeNewswire August 22, 2022

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2022

ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress

GlobeNewswire August 11, 2022